DSIJ Mindshare

According to the quarterly results, the net sales increased by 43.14 per cent to Rs 138.16 crore, operating profit increased by 10.24 per cent to Rs 9.8 crore and net profit increased by 14.58 per cent to Rs 4.4 crore in Q1FY24 compared to Q1FY23.

According to the quarterly results, the net sales decreased by 6.79 per cent to Rs 1,702 crore, operating profit increased by 33.33 per cent to Rs 132 crore and net profit increased by 9.30 per cent to Rs 47 crore in Q1FY24 compared to Q1FY23. In FY23, the net sales increased by 64.69 per cent to Rs 6,927 crore and net profit increased by 47.74 per cent to Rs 164 crore compared to FY22.

The USDINR Futures contracts, as well as the USDINR Option contract on NSE, are globally the largest contracts in their respective categories based on the number of contracts traded in the calendar year 2022, according to statistics published by the Futures Industry Association (FIA), a derivatives trade body.

In fiscal year 2022-23 (FY23), the company's net sales grew by 62.85 per cent to Rs 513 crore, compared to Rs 315 crore in FY22. It also reported a net profit of Rs 3 crore in FY23, a significant improvement from the net loss of Rs 25 crore in FY22.

The marketing approval for Enoxaparin in Saudi Arabia is anticipated to pave the way for similar authorizations in other GCC and MENA countries. This anticoagulant holds significance in treating cardiovascular diseases, a notable health concern in Saudi Arabia, and is expected to contribute to the burgeoning global Enoxaparin market.